Not a good buy right now: price action and momentum are decisively bearish (SMA_200 > SMA_20 > SMA_5 and MACD histogram negative and worsening), which is unfavorable for an impatient entry.
Near-term probabilities also lean lower (pattern study suggests ~-2.29% next day and ~-2.89% next week), so the path of least resistance is still down.
Oversold conditions (RSI-6 ~22.5) can spark bounces, but without a bullish signal (no Intellectia AI Stock Picker / SwingMax) this is more likely a short-lived rebound than a trend reversal.
Net: avoid buying pre-market at ~20.53; this is a “wait/hold-off” setup rather than a clean buy-now opportunity.
Technical Analysis
Trend/Momentum: Bearish structure with moving averages stacked down (SMA_200 > SMA_20 > SMA_5), indicating a sustained downtrend.
MACD: Histogram at -0.248 and negatively expanding → downside momentum is increasing, not stabilizing.
RSI: RSI_6 ~22.49 suggests oversold conditions (bounce potential), but oversold alone is not a reversal signal.
Levels to watch: Immediate support S1 ~20.736 (very close to current ~20.5–20.7); if it breaks, next support S2 ~19.818. Overhead pivot resistance ~22.222, then R1 ~23.708.
Tactical read: Risk/reward is poor for an impatient buyer while trading below the pivot (22.222) and with momentum still deteriorating.
Options Data
Bullish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio
Positioning vs. flow is mixed: very low OI put/call (0.11) suggests longer-dated/open positioning is call-heavy (constructive).
But today’s volume put/call is high (2.24) with volume spike (today vs 30D avg ~766.67%) → short-term sentiment/hedging leans bearish or defensive.
Volatility: 30D IV ~68% (IV percentile ~62) and above HV ~83% relationship suggests options are expensive but not extreme; the market is pricing meaningful movement.
Net options takeaway: longer-term participants appear optimistic, but near-term traders are buying puts/hedging—consistent with a fragile near-term tape.
Technical Summary
Sell
5
Buy
7
Positive Catalysts
Upcoming catalyst: Earnings on 2026-02-17 (pre-market) could reset narrative if licensing/royalty momentum continues.
Neutral/Negative Catalysts
Short-term options flow is defensive (put-heavy volume), aligning with near-term downside caution.
Financial Performance
Latest quarter: 2025/Q3
Revenue: $28.384M, +4.33% YoY (modest growth).
Profitability: Net income - $2.509M (still a loss) but improved ~91.38% YoY (loss narrowing materially).
EPS: -0.10, improved ~66.67% YoY.
Gross margin: 87.52%, up ~3.10% YoY → strong unit economics; key is scaling revenue/licensing to reach sustained profitability.
Overall: improving fundamentals, but not yet profitable—near-term price action may remain sensitive to sentiment and earnings expectations.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent trend: bullish—both Barclays (Overweight) and Roth Capital (Buy) raised price targets to $35 from $30 following Q3 strength.
Wall Street pros: broad end-market royalty growth, robust licensing results, and growing NeuPro AI IP licensing contribution supporting a secular growth story.
Wall Street cons: current share performance contradicts fundamentals (bearish tape), and profitability is still negative—execution risk remains until consistent earnings power emerges.
Wall Street analysts forecast CEVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CEVA is 36 USD with a low forecast of 33 USD and a high forecast of 40 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast CEVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CEVA is 36 USD with a low forecast of 33 USD and a high forecast of 40 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 20.940
Low
33
Averages
36
High
40
Current: 20.940
Low
33
Averages
36
High
40
Barclays
Tavy Rosner
maintain
$30 -> $35
AI Analysis
2025-11-11
Reason
Barclays
Tavy Rosner
Price Target
$30 -> $35
AI Analysis
2025-11-11
maintain
Reason
Barclays analyst Tavy Rosner raised the firm's price target on Ceva to $35 from $30 and keeps an Overweight rating on the shares.
Roth Capital
Buy
upgrade
$30 -> $35
2025-11-10
Reason
Roth Capital
Price Target
$30 -> $35
2025-11-10
upgrade
Buy
Reason
Roth Capital raised the firm's price target on Ceva to $35 from $30 and keeps a Buy rating on the shares. The company's Q3 results topped estimates, and the firm is encouraged by broad end market royalty growth and robust licensing results, the analyst tells investors in a research note. The growing NeuPro AI IP licensing contribution bodes well for the secular growth opportunity, the firm added.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CEVA
